Sabra Health Care REIT, Inc. Earnings Per Share Disclosure
| Year Ended December 31, | |||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||
| Numerator | |||||||||||||||||
| Net income attributable to Sabra Health Care REIT, Inc. | $ | 155,609 | $ | 126,712 | $ | 13,756 | |||||||||||
| Denominator | |||||||||||||||||
| Basic weighted average common shares and common equivalents | 241,312,309 | 233,498,736 | 231,203,391 | ||||||||||||||
| Dilutive restricted stock units | 2,871,902 | 2,446,335 | 1,589,387 | ||||||||||||||
| Dilutive forward equity sale agreements | 313,031 | 100,791 | — | ||||||||||||||
| Diluted weighted average common shares | 244,497,242 | 236,045,862 | 232,792,778 | ||||||||||||||
| Net income attributable to Sabra Health Care REIT, Inc., per: | |||||||||||||||||
| Basic common share | $ | 0.64 | $ | 0.54 | $ | 0.06 | |||||||||||
| Diluted common share | $ | 0.64 | $ | 0.54 | $ | 0.06 | |||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 12, 2026 | Showing above |
| 2024 | Feb 19, 2025 | |
| 2023 | Feb 27, 2024 | |
| 2022 | Feb 21, 2023 | |
| 2021 | Feb 22, 2022 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.